Transfusion
January 2019
Background: Plerixafor (PFX) mobilizes CD34+ cells into circulation by disrupting the CXCR4 binding of the hematopoietic stem cell in its bone marrow niche.
Study Design And Methods: in the prospective HOVON-107 study (www.hovon.